98%
921
2 minutes
20
This study aims to identify the chemical structure and immunomodulatory activity of exopolysaccharides (EPSs) from BJ01 and suggest its potential applications in the pharmaceutical field and as functional food additives. The EPS-1 produced by . BJ01 was purified using column chromatography. The lyophilized powder obtained by vacuum freeze-drying was used for structural characterization and immunomodulatory activity analysis. Gel permeation chromatography (GPC) determined its molecular weight as 156.58 kDa. High-performance anion-exchange chromatography (HPAEC) identified that the EPS-1 is composed of mannose, xylose, and glucose. The structural characterization of EPS-1 by gas chromatography-mass spectrometry (GC-MS) and 1D/2D nuclear magnetic resonance (NMR) spectroscopy demonstrated that EPS-1 is primarily composed of α-D-Man-(1→, →2,6)-α-D-Man-(1→, →2)-α-D-Man-(1→, and →3)-α-D-Man-(1→. Scanning electron microscopy (SEM) and atomic force microscopy (AFM) illustrated that EPS-1 exhibited a round, flake-like morphology. In vitro experiments with RAW264.7 macrophages demonstrated the high immunomodulatory activity of EPS-1. Significant upregulation of iNOS, IL-6, and TNF-α mRNA levels was confirmed by qRT-PCR ( < 0.05). Western blotting revealed that EPS-1 (6.25 μg/mL) induced phosphorylation of NF-κB (p65, IκBα) and MAPK (ERK) signaling proteins. This study provides the first structural and immunomodulatory characterization of an exopolysaccharide from BJ01, highlighting its potential as a novel immune adjuvant.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12249100 | PMC |
http://dx.doi.org/10.3390/foods14132162 | DOI Listing |
Trends Biotechnol
September 2025
Department of Oral and Cranio-maxillofacial Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laborator
Type 2 diabetes (T2D) is characterized by persistent and unresolved tissue inflammation caused by the infiltration and dysregulation of immune cells. Current therapeutics targeting inflammatory immune cells for T2D remain limited. In this study, we analyzed single cell RNA from metabolic organs in T2D, revealing increased macrophage accumulation and a pathogenic macrophage subpopulation defined as NOD-like receptor (NLR) family pyrin domain-containing 3 (NLRP3) inflammatory and metabolically activated macrophages.
View Article and Find Full Text PDFImmunol Lett
September 2025
Department of Clinical and Translational Science, College of Graduate Health Science, University of Tennessee Health Science Center, Memphis, Tennessee. Electronic address:
Background: Patients with chronic lung diseases often suffer from pulmonary aspergillosis, caused by Aspergillus fumigatus (AF). Alveolar macrophages play a key role in the initial immune response to AF. Azithromycin (AZM), commonly known for its immunomodulatory properties in reducing exacerbations and improving lung function, has mixed effects on the development of aspergillosis.
View Article and Find Full Text PDFInt J Pharm
September 2025
Department of Pharmaceutical Sciences, Via del Liceo 1, 06123 Perugia, Italy. Electronic address:
Indole-3-carboxaldehyde (I3A), a microbial tryptophan metabolite, exhibits significant immunomodulatory activity at the host-microbial interface. However, its rapid transformation into metabolites like indole-3-carboxylic acid (I3CA) raises questions about their therapeutic potential. This study aimed to evaluate the pharmacological contributions of I3CA through the development of a proper delivery strategy.
View Article and Find Full Text PDFPathol Res Pract
September 2025
Department of Biotechnology, Delhi Technological University, India. Electronic address:
The intricate interplay between cancer and autoimmune diseases (ADs) is rooted in immune dysregulation, where genetic susceptibility, chronic inflammation, epigenetic modifications, and immunosuppressive therapies contribute to tumorigenesis. The dualistic nature of immune activation complicates therapeutic strategies, as immune checkpoint inhibitors and other immune-stimulatory therapies may exacerbate underlying ADs, leading to immune-related adverse events (irAEs), including organ toxicity, dermatologic reactions, and disease flares. Conversely, immunosuppressive treatments aimed at controlling ADs can compromise anti-tumor immunity and reduce the efficacy of cancer therapies.
View Article and Find Full Text PDFJCI Insight
September 2025
Division of Nephrology, Boston University Chobanian & Avedisian School of Medicine, Boston, United States of America.
Background: Active vitamin D metabolites, including 25-hydroxyvitamin D (25D) and 1,25-dihydroxyvitamin D (1,25D), have potent immunomodulatory effects that attenuate acute kidney injury (AKI) in animal models.
Methods: We conducted a phase 2, randomized, double-blind, multiple-dose, 3-arm clinical trial comparing oral calcifediol (25D), calcitriol (1,25D), and placebo among 150 critically ill adult patients at high-risk of moderate-to-severe AKI. The primary endpoint was a hierarchical composite of death, kidney replacement therapy (KRT), and kidney injury (baseline-adjusted mean change in serum creatinine), each assessed within 7 days following enrollment using a rank-based procedure.